CN1022487C - 制备新的药物化合物 - Google Patents
制备新的药物化合物 Download PDFInfo
- Publication number
- CN1022487C CN1022487C CN86107595A CN86107595A CN1022487C CN 1022487 C CN1022487 C CN 1022487C CN 86107595 A CN86107595 A CN 86107595A CN 86107595 A CN86107595 A CN 86107595A CN 1022487 C CN1022487 C CN 1022487C
- Authority
- CN
- China
- Prior art keywords
- carbon atom
- compound
- alkyl
- formula
- contain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 131
- 230000000144 pharmacologic effect Effects 0.000 title description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 113
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- 125000003545 alkoxy group Chemical group 0.000 claims description 45
- -1 ammonium salt ion Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 33
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 239000003513 alkali Substances 0.000 claims description 11
- 125000003368 amide group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 150000001457 metallic cations Chemical class 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims 20
- 239000007858 starting material Substances 0.000 claims 13
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical group [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 110
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 44
- 239000000203 mixture Substances 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000027119 gastric acid secretion Effects 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000004171 alkoxy aryl group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 150000008282 halocarbons Chemical class 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- SGXDXUYKISDCAZ-UHFFFAOYSA-N N,N-diethylglycine Chemical compound CCN(CC)CC(O)=O SGXDXUYKISDCAZ-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 125000005133 alkynyloxy group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229950010118 cellacefate Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- WFPZPJSADLPSON-UHFFFAOYSA-N dinitrogen tetraoxide Chemical compound [O-][N+](=O)[N+]([O-])=O WFPZPJSADLPSON-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- VQMSRUREDGBWKT-UHFFFAOYSA-N quinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=NC2=C1 VQMSRUREDGBWKT-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- JSLZUBLGGPEVQN-DIPNUNPCSA-N (2r)-4-methyl-2-propan-2-yl-2-[2-[4-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]piperazin-1-yl]butoxy]phenyl]-1,4-benzothiazin-3-one Chemical compound COC1=C(OC)C(OC)=CC(CCN2CCN(CCCCOC=3C(=CC=CC=3)[C@@]3(C(N(C)C4=CC=CC=C4S3)=O)C(C)C)CC2)=C1 JSLZUBLGGPEVQN-DIPNUNPCSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- INOGLHRUEYDAHX-UHFFFAOYSA-N 1-chlorobenzotriazole Chemical compound C1=CC=C2N(Cl)N=NC2=C1 INOGLHRUEYDAHX-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000035944 Duodenal fistula Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010065713 Gastric Fistula Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ITATYELQCJRCCK-UHFFFAOYSA-N Mandelic Acid, Methyl Ester Chemical group COC(=O)C(O)C1=CC=CC=C1 ITATYELQCJRCCK-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- JMOXSQYGVIXBBZ-UHFFFAOYSA-N N,N-dimethyl-beta-alanine Chemical compound CN(C)CCC(O)=O JMOXSQYGVIXBBZ-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- VAKKJWXZRREDEX-UHFFFAOYSA-N [O].CC#CC Chemical compound [O].CC#CC VAKKJWXZRREDEX-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N anhydrous methyl chloride Natural products ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- SMJYMSAPPGLBAR-UHFFFAOYSA-N chloromethyl acetate Chemical compound CC(=O)OCCl SMJYMSAPPGLBAR-UHFFFAOYSA-N 0.000 description 1
- BOXZXICVMMSYPE-UHFFFAOYSA-N chloromethyl benzoate Chemical compound ClCOC(=O)C1=CC=CC=C1 BOXZXICVMMSYPE-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000005171 halobenzenes Chemical class 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- JYJVVHFRSFVEJM-UHFFFAOYSA-N iodosobenzene Chemical compound O=IC1=CC=CC=C1 JYJVVHFRSFVEJM-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950001891 iprotiazem Drugs 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 150000002976 peresters Chemical class 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- BOTNYLSAWDQNEX-UHFFFAOYSA-N phenoxymethylbenzene Chemical compound C=1C=CC=CC=1COC1=CC=CC=C1 BOTNYLSAWDQNEX-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006225 propoxyethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 239000012629 purifying agent Substances 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036259 sexual stimuli Effects 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 150000003504 terephthalic acids Chemical class 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Abstract
制备结构式如下的新化合物,含有它们作为活性成分的药物制剂及这些化合物在医药中的应用。
Description
本发明的目的是提供一些新的化合物及其可用于治疗的盐类。这些化合物可抑制外原性或内原性刺激的胃酸分泌,因此可用于予防和治疗消化性溃疡。
本发明是关于应用本发明的化合物或其可用于治疗的盐,抑制哺乳类动物和人的胃酸分泌。从更广义来说,本发明的这些化合物可用于预防和治疗哺乳类动物和人的胃肠道炎症,包括为胃炎、胃溃疡和十二指肠溃疡。此外,这些化合物还可用于其他需要抑制胃分泌的胃肠道紊乱,如促胃液素瘤病人、急性上胃肠道出血及长期饮酒过度的病人。本发明也与至少含有本发明的一个化合物或其可用于治疗的盐,作为有效成分的药物组合物有关。此外,本发明还涉及这些新化合物的制备方法、制备本发明的化合物中的新中间体、及上述医疗用药物组合物制备中的活性化合物的应用。
英国专利说明书1,500,043和1,525,958、美国专利4,182,766、欧洲专利说明书0,005,129和比利时专利说明书890,024中公开了打算把苯并咪唑衍生物用于抑制胃酸分泌。欧洲专利申请公布号0,045,200公开了建议把苯并咪唑衍生物用于治疗或予防特殊的胃肠道炎症。
已发现式Ⅰ化合物及其生理上可用的盐类在哺乳类动物和人中作为胃酸分泌抑制剂是有效的
其中X是-S-或-SO-;
R1、R2、R3和R4可相同或不同,它们是
(a)H
(b)含1~6个碳原子的烷基
(c)含3~7个碳原子的环烷基
(d)含1~6个碳原子的烷氧基
(e)各烷基部分上含1~3个碳原子的烷氧基烷基
(f)各烷基部分上含1~3个碳原子的烷氧基烷氧基
(g)卤素
(h)-CN
(i)-CF3
(j)-NO2
(k)-COR10
(l)烷基部分含1~6个碳原子的烷硫基
(m)烷基部分含1~7个碳原子的烷基亚磺酰基
(n)芳基
(o)烷基部分含1~6个碳原子的芳基烷基
(p)芳氧基
(q)含1~6个碳原子的和1~6个卤原子的卤代烷氧基
(r)烷基部分含1~6个碳原子的芳基烷氧基
(s)R1和R2、R2和R3或者R3和R4与其在苯并咪唑环上的相连的碳原子形成1个或多个五、六或七元环,这些环可以是饱和的或不饱和的,它们可以含有0~3个选自N、S和O的杂原子,各环可以任意地被1~10个,最好是1~6个或1~4个选自1~3个碳原子的烷基和卤素的取代基取代,或者2或4个上述的取代基一起形成1或2个含氧基团(
),由此,如果R1和R2、R2和R3或R3和R4和在苯并咪唑环上与其相连的碳原子形成两个环,这些环可能互相稠合。
R5是(a)含1~6个碳原子的烷基
(b)含1~6个碳原子的单或二羟基取代的烷基
(c)氨基、单烷基(1~3个碳原子)-氨基、及二烷基(各烷基部分含1~3个碳原子)-氨基取代的含1~6个碳原子的烷基,也可取其盐的形式,如氯化氢盐
(d)羧基取代的含1~7个碳原子的烷基,可任选作盐的形式,如钠或钾盐
(e)含3~7个碳原子的环烷基
(f)含1~6个碳原子的烷氧基
(g)单或二羟基取代的含1~6个碳原子的烷氧基
(h)氨基、单烷基(1~3个碳原子)-氨基,和二烷基(各烷基部分含1~3个碳原子)-氨基取代的含1~6个碳原子
的烷氧基、可任选作盐的形式,如氯化氢盐
(i)羧基取代的含1~7个碳原子的烷氧基、可任选作盐的形式,如钠盐或钾盐
(j)各烷基部分含1~3个碳原子的烷氧基烷氧基
(k)含1~6个碳原子的烷基氨基
(l)各烷基部分含1~4个碳原子的二烷基氨基
(m)烷基部分含1~4个碳原子的单或二羧基取代的烷基氨基,可任选作盐的形式、或酯化形式,特别是在烷基部分含有1~4个碳原子的单或二烷基酯的形式、或者单或二苄基酯的形式。
(n)由含1~4个碳原子的烷基、含1~4个碳原子的烷氧基、卤素、CF3、含2~5个碳原子的酰基、含2~5个碳原子的烷氧羰基或羧基所任意取代的芳基,其中羧基可任选作盐的形式;如钠盐。
(o)由含1~4个碳原子的烷基、含1~4个碳原子的烷氧基、卤素、CF3、含2~5个碳原子的酰基、含2~5个碳原子烷氧羰基或羧基所任意取代的芳氧基,其中羧基可任选作盐的形式,如钠盐。
(p)烷氧基部分含1~6个碳原子的芳基烷氧基,其中芳基部分由含1~6个碳原子的烷基、和/或含1~6个碳原子的烷氧基、或可任选作盐(如钠盐)形式的羧基所任意取代。
R6和R8是相同的或不相同的,选自:
(a)H
(b)含1~6个碳原子的烷基
R7是(a)H
(b)含1~7个碳原子的烷基
(c)含1~7个碳原子的烷氧基
(d)芳基
(e)烷基部分含1~7个碳原子的芳基烷基
(f)芳氧基
(g)烷氧基部分含1~7个碳原子的芳基烷氧基
(h)链烯基部分含1~7个碳原子的链烯氧基
(i)炔基部分含1~7个碳原子的炔氧基
(j)烷基部分含1~7个,最好是1~3个碳原子的烷硫基
(k)芳硫基
(l)烷基部分含1~7个,最好是1~3个碳原子的芳基烷硫基
(m)各烷基部分含有1~7个,最好是1~3个碳原子的二烷基氨基
(n)吗啉代
(o)哌啶子基
或者R6和R7、或者R7和R8,与其在吡啶环上相连的碳原子形成一个五元或六元,饱和或不饱和的环,环上可任意含有氧、硫或任意烷基化的氮原子。
R9是(a)H
(b)含1~4个碳原子的烷基
R10是(a)含1~6个碳原子的烷基
(b)含1~6个碳原子的烷氧基
但须:
(a)当下列(a1)~(a3)条件同时满足时,R7是氢、烷基、芳基或芳烷基:
(a1)R1和R4都是氢
(a2)R2和R3选自氢、烷基、烷氧基、CF3或COR10和
(a3)R5是烷基、酸形式的羧基取代的烷基、氨基取代的烷基、或R5是由烷基、烷氧基、卤素或CF3取代的芳基。
(b)当R1、R2、R3、R4、R5、R6、R7、R8和R9是氢和X是S时,R5不是2-甲基丙氧基。
此外,本发明还包括下面例2和例3的两个化合物,它们具有与式Ⅰ化合物相同的发明方面。
本发明的亚砜(X=SO)化合物的硫原子是不对称中心,即这些化合物以两个光字异构(对映异构体)存在,如果它们还含有一个或多个不对称碳原子,那末这些化合物有两个或更多的非对映体,各自又存在于两个对映体中。
纯的对映异构体、外消旋混合物(各对映异构体占50%)及此二者的不等量的混合物,都属于本发明的范畴。应该这样来理解,所有的可能的非对映异构体的形式(纯的对映异构体或外消旋混合物)都在本发明的范畴内。
本发明的硫醚(X=S)类化合物,由于如上述的一个或多个不对称碳原子,可能成为不对称。这些可能的不同的非对映异构体以及纯的对映体和外消旋混合物都在本发明范畴内。
较好的式Ⅰ化合物是
1.X是-SO-的化合物。
2.X是-S-的化合物。
3.R1、R2、R3和R4相同或不相同,分别选自下列基团的化合物:
(a)H
(b)含1~6个碳原子的烷基
(c)烷基部分含1~6个碳原子的烷氧基,或
(d)R2和R3与其在苯并咪唑环上相连的碳原子一起形成只含碳原子的、饱和的或不饱和的五元或六元环。
(e)R2和R3与其在苯并咪唑环上相连的碳原子一起形成含碳原子和氧原子的、饱和的或不饱和的、五元或六元环。
4.R1、R2、R3和R4是氢、含1~6个碳原子的烷基、或含1~6个碳原子的烷氧基的化合物。
5.R1和R4是氢、R2和R3都是含1~6个碳原子的烷基的化合物。
6.R5是下列基团的化合物:含1~6个碳原子的烷基,特别是甲基;含1~6个碳原子的烷氧基;芳基,特别是未取代的或被羧基(最好是其盐的形式)取代的苯基;单和二羟基取代的含1~6个碳原子的烷基;单和二羟基取代的含1~6个碳原子的烷氧基;羧基取代的含1~7个碳原子的烷基,其羧基取盐的形式;羧基取代的含1~7个碳原子的烷氧基,其羧基可以是盐的形式的;单或二羧基取代的,在烷基部分含1~4个碳原子的烷基氨基;氨基、单烷基(1~3个碳原子)-氨基和二烷基(各烷基部分含1~3个碳原子)-氨基取代的含1~6个碳原子的烷基,可任选作盐,如氯化氢盐的形式;氨基、单烷基(1~3个碳原子)-氨基和二烷基(各烷基部分含1~3个碳原子)-氨基取代的含1~6个碳原子的烷氧基,可任选作盐,如氯化氢盐的形式。
7.R5是羧基取代的苯基的化合物,最好羧基是在苯环的4-位
上。
8.R5是盐的形式的二烷基(1~3个碳原子)-氮基取代的烷基(1~6个碳原子)的化合物。
9.R5是盐的形式的二烷基(1~3个碳原子)-氨基取代的,含1~6个碳原子的烷氧基的化合物。
10.R1、R2、R3和R4都是氢的化合物。
11.当R2和R3是氢时,R1和R4是含1~6个碳原子的烷基的化合物。
12.R1、R3和R4是氢且R2是甲氧基,式R1、R2和R4是氢且R3是甲氧基的化合物。
13.R7是氢、含1~6个碳原子的烷基或含1~6个碳原子的烷氧基的化合物。
14.R7是含1~6个碳原子的烷基或含1~6个碳原子的烷氧基的化合物。
15.R7是含1~6个碳原子的烷氧基的化合物。
16.R9是氢或甲基,特别是氢的化合物。
17.在苯并咪唑核1-位上的较好的取代基是:
-CH(CH3)OCOOC2H5
-CH2OCOOC2H5
-CH2OCOOCH2CH(CH3)3
-CH2OCOOCH2CH(OH)CH2OH
-CH2OCOCH2CH2CH2CH2COO-Na+
-CH2OCOCH2N(CH3)2
-CH2OCOCH2N(C2H5)2
-CH2OCOCH2CH2N(CH3)2
-CH2OCOCH2CH2N(C2H5)2
-CH2OCOCH2CH2CH2N(CH3)2
-CH2OCOOCH2CH2N(CH3)2
-CH2OCOOCH2N(CH3)2
-CH2OCONHCH2COOH
其中含氨基的基团任选作盐的形式,羧基任选作盐或酯的形式。
18.较好的苯并咪唑的结构是:
上述1~17条指出的某些或全部X和R1~R10代表的基团中,将其中优先选用的基团结合,是另外一些较好的化合物。特别好的结合的例子是:
19.1、3、6、14和18相结合
20.较好的吡啶部分是
21.较好的吡啶部分是
22.较好的吡啶基甲基亚磺酰基苯并咪唑部分是:
23.较好的R6和R8基是氢、甲基和乙基。在R1、R2、R3、R4、R5、R6、R7、R8和R10的定义中的烷基,最好是低级烷基,特别是1~4个碳原子的,为甲基、乙基、正丙基、异丙基、正丁基或异丁基。R1、R2、R3、R4、R7和R10定义中的烷氧基最好是低级烷氧基,特别是1~3个碳原子的,如甲氧基、乙氧基、正丙氧基或异丙氧基。
R1、R2、R3、R4和R5的定义中的卤素最好是氯、溴、氟和碘。
当R1、R2、R3、R4和R7代表烷硫基或烷基亚磺酰基时,烷基最好是低级烷基,特别是1~4个碳原子的,如甲硫基、甲亚磺酰基、乙硫基、乙亚磺酰基、异丙硫基、正丁亚磺酰基或异丁硫基。R1、R2、R3、R4、R5和R7代表芳基时,最好是多至10个碳原子特别是多至6个碳原子,如苯基。
R1、R2、R3、R4、R5和R7代表芳氧基时,最好是多至10个碳原子,特别是6个碳原子,如苯氧基。R1、R2、R3、R4、R5和R7代表芳烷基或芳烷氧基时,芳基部分最好多至10个碳原子。最好芳基是6子碳原子,烷基或烷氧基分别是1~3个碳原子,如苯甲基、苯乙基、苯甲氧基、苯乙氧基、苯丙基和苯异丙氧基。
R1、R2、R3、R4、和R5代表环烷基时,最好是3~7个碳原子,特别好的是5~6个碳原子,如环戊基、环己基和甲基环戊基。
R1、R2、R3、R4和R5代表烷氧基烷基或烷氧基烷氧基,最好是烷氧基或两个烷氧基和烷基分别含1~6个碳原子,特别好的是烷氧基或两个烷氧基和烷基分别含1~3个碳原子,如甲氧基乙基、甲氧基丙基、乙氧基乙基、丙氧基乙基、甲氧基乙氧基、甲氧基丙氧基、乙氧基乙氧基和丙氧基乙氧基。
R7代表烯氧基或炔氧基时,最好是2~7个碳原子,特别好的是3~4个碳原子,如烯丙氧基、炔丙氧基、2-丁烯氧基和2-丁炔氧基。
由R1和R2、R2和R3及R3和R4形成环结构的说明性的例子是-CH2CH2CH2-、-CH2CH2CH2CH2-、-CH2C(CH3)2CH2-、-(CH2)5-、-CH=CH-CH=CH-、-CH2COCH2-、-OCH2O-、-OCH2CH2O-、-OCH2CH2CH2O-、-OCH2CH2-、-CH2CH2
NH-、-CH=CH-CH=N-、-COCH2CO-、-SCH2CH2-、CH2S-、-SCH2CH2S-和-C(CH3)2-CO-C(CH3)2-。
R6和R7,或R7和R8代表五元或六元饱和或不饱和环,最好是饱和的碳环系或在吡啶环的4-位上带氧原子的饱和环系,如-CH2CH2CH2-、-CH2CH2CH2CH2-、-O-CH2CH2-或-O-CH2CH2CH2-。
当R5和R7代表烷基氨基或二烷基氨基时,最好是-NHCH3、-NHC2H5、-N(CH3)2、-N(C2H5)2或-NHCH(CH)2。
当R5代表氨基、单烷基氨基和二烷基氨基取代的烷基时,氨基上各烷基取代基最好含1~3个碳原子。氨基、单烷基氨基或二烷基氨基最好是连在含1~3个碳原子的烷基上。
当R5代表氨基、单烷基氨基和二烷基氨基取代的烷氧基时,氨基上的各烷基取代基最好含1~3个碳原子。氨基,单烷基氨基或二烷基氨基最好是连在含1~3个碳原子的烷氧基上。
式Ⅰ的含有不对称中心的化合物,其纯的对映异构体和外消旋混合物,均在本发明的范围内。
式Ⅰ的基团的进一步说明性的例子在下面的举例中和本说明中另外列出的特定化合物的表中进一步说明。
本发明范围内的化合物的举例说明列在下表1中。
本发明考虑到式Ⅰ的化合物在起作用前就被代谢了,这种代谢可能发生在苯并咪唑核的1-位的N-取代基上。此外,据信,本发明的X是S的化合物,在代谢成X是SO的化合物之后,起抗分泌的作用。
此外据信,式Ⅰ的X是SO的所有的化合物在对活的生物体给药
之后,在经过代谢或纯的化学变化而成为其他的有活性的形式后,有抑制分泌的作用。相应地,这一点对式Ⅰ的X是S的化合物也是一样的,但是它先转变成相应的X是SO的式Ⅰ化合物。
制备
式1的化合物可如下制备:
A.式Ⅱ的化合物与式Ⅲ的化合物反应
其中,R1、R2、R3、R4、R6、R7、R8和X如式Ⅰ下的规定,M或者是金属阳离子,如Na+、K+和Li+,或者是四级铵离子,如四丁铵离子;
其中R5和R9如式Ⅰ下的规定;Y是卤素,如氯、溴或碘,或功能相当的基团。
式Ⅱ化合物与式Ⅲ化合物的反应适于在有保护气体和无水的情况下进行,适宜的溶剂是碳氢化合物,如甲苯和苯,和卤代碳氢化合物,如二氯甲烷和氯仿。
式Ⅱ和式Ⅲ化合物的反应可在室温和反应混合物沸腾温度之间进
行。
B.式Ⅰ化合物的氧化
其中X是硫,R1、R2、R3、R4、R5、R6、R7、R8和R9的意义已给出,这样就得到X是SO的式Ⅰ化合物。进行此氧化反应可选用下述氧化剂:硝酸、过氧化氢、过酸、过酸酯、氧、四氧化二氮、亚碘酰苯、N-卤代琥珀酰亚胺、1-氯苯并三唑、次氯酸特丁基酯、二氮杂二环-(2,2,2)-辛烷溴洛合物、偏高碘酸钠、二氧化硒、二氧化锰、铬酸、硝酸高铈胺、溴、氯和硫酰氯。通常此氧化反应在溶剂中进行,氧化剂相对于被氧化物是稍过量的。
此氧化反应也可用氧化酶进行酶菌氧化或用适宜的微生物进行微生物氧化。
C.R9是氢的式Ⅰ化合物由式Ⅳ化合物与式Ⅴ化合物、或其活化衍生物反应制备。
式Ⅳ中的R1、R2、R3、R4、R6、R7、R8和X如式Ⅰ下定义。式Ⅴ中的R5同上述式Ⅰ下规定。
式Ⅳ化合物与式Ⅴ化合物的反应适于或者直接在二环己基碳二亚胺。需要时还在有N,N-二甲基氨基吡啶(DMAP)的存在下进行,或者与化合物Ⅴ的活化形式,如酰卤、或混合酸酐,或羧酸酯。
适宜的溶剂是碳氢化合物,如甲苯和苯、或卤代碳氢化合物,如二氯甲烷和氯仿、或极性溶剂,如丙酮、二甲基甲酰胺(DMF)、四氢呋喃(THF)和吡啶。
式Ⅳ化合物与式Ⅴ化合物的反应可在-15℃和反应混合物的沸腾温度之间进行。
D.在式Ⅰ中,当R9是氢,且R5基上有氨基、单烷基氨基或二烷基氨基取代时,可用式Ⅵ化合物与式Ⅶ化合物反应,制备该式Ⅰ化合物,
式Ⅵ中,R1、R2、R3、R4、R6、R7、R8和X同式Ⅰ下定义,Z是卤素,如氯,或功能相当的基团;式Ⅶ中R11和R12可相同或不同,是氢或含1~6个碳原子的烷基。
此反应在适宜的溶剂,如丙酮或乙腈中,在室温和反应混合物的沸腾温度之间的温度中进行。
E.若式Ⅰ中R9是H,R5是含1~6个碳原子的单烷基氨基,可用式Ⅳ化合物与式Ⅷ化合物反应制备该式Ⅰ化合物,
其中R1、R2、R3、R4、R6、R7、R8和X如式Ⅰ下规定;
其中,R13是含1~6个碳原子的烷基,
式Ⅷ化合物与式Ⅳ化合物的反应或者直接进行,或者需要时在适宜的碱,如吡啶或N,N-二甲基氨基吡啶的存在下进行。适宜的溶剂是碳氢化合物,如甲苯和苯,或是卤代碳氢化合物,如二氯甲烷和氯仿。式Ⅳ和式Ⅷ化合物的反应可在室温和反应混合物的沸腾温度之间的温度下进行。
F.式Ⅰ化合物的R5取代基上保护基团的脱下。这一点可用精于此技术的人所熟知的几种方法来实现。例如,单羟基烷基可以被保护成酯基,可以用水解脱下;成对的二羟基烷基或成对的二羟基烷氧基可被保护成丙酮化物,可以用酸水解脱下;氨基和单烷基氨基-烷基或氨基和单烷基氨基-烷氧基作为R5,可由叔丁氧基羰基(t-Boc)基团保护,可用酸处理脱下之;R5是羧基烷基或羧基-烷氧基,可以保护成酯,其可水解脱下。
根据工艺条件和原料,式Ⅰ的最终产物或者以游离碱,或者作为盐而得到。最终产物的游离碱和盐二者均属于本发明的范畴。盐还可以作为半、单、一倍半或多水合物的形式得到。新化合物的酸加成盐可用已知方法,用碱性试剂如碱或离子交换,变成游离碱。得到的游离碱也可用有机或无机酸成盐。制备酸加成盐最好选用能生成适于治疗用的盐的酸,例如氢卤酸、磺酸、磷酸、硝酸、高氯酸;脂肪的、脂环的、芳香的或杂环的羧酸或磺酸,如甲酸、乙酸、丙酸、琥珀酸、乙二酸、乳酸、苹果酸、酒石酸、柠檬酸、抗坏血酸、马来酸、羟基马来酸、丙酮酸、苯乙酸、苯甲酸、对氨基苯甲酸、对羟基苯甲酸、
水杨酸或对氨基水杨酸、萘酸(embonic acid)、甲磺酸、乙磺酸、羟乙磺酸、亚乙基二磺酸、卤苯磺酸、甲苯磺酸、萘磺酸或对氨基苯磺酸、蛋氨酸、色氨酸、赖氨酸或精氨酸。
这些新的硫醚类化合物的这些或其他的盐,如苦味酸盐,可用作所得的游离碱的纯化剂。生成的碱的盐,从溶剂中分离出来。然后从新的盐溶液中回收到更高纯度的游离碱。
可用已知的方法分离得到的外消旋物,例如在光学活性的溶剂中重结晶,应用微生物、与光学活性的酸反应,生成可以分离的非对映异构盐(例如基于非对映异构体不同的溶解度来分离)、用光学活性的活化的羧酸(如酰氯)酰化取代基上的氮原子或氧原子,然后层析分离和去酰化。
适于成盐的光学活性酸有:L-和D-型酒石酸、二-邻-甲苯基酒石酸、苹果酸、扁桃酸、樟脑磺酸或金鸡钠酸;适于酰化的有:邻甲基扁桃酸。最好是析离出两个对映体活性较大的部分。
在非对映异构体混合物(外消旋混合物)的情况下,可用层析或分级结晶的方法,分离成立体异构的(非对映的)纯的外消旋体。
在方法A~E中使用的原料有些是新的,但这些新原料可按已知的方法制得。
式Ⅲ、Ⅳ、Ⅴ、Ⅵ、Ⅶ和Ⅷ的原料可按已知的方法制得。式Ⅲ的原料可由酰氯R5COCL同含酮基的R9CHO化合物在氯化锌的存在下处理得到如下例。式Ⅵ的原料可由式Ⅳ化合物与卤代羧酸酰氯反应制备。式Ⅳ的原料可如下面“中间体制备”例举的方法制得。
式Ⅲ、Ⅳ、Ⅴ、Ⅵ、Ⅶ和Ⅷ的化合物有些是新的,构成本发明的相应的部分。特别是式Ⅳ化合物,其代表本发明的一个部分。
在方法B中所用的含X=S的原料可根据方法A制得。
为了临床的使用,本发明的化合物配成供口服、直肠、胃肠道外或其他给药方式的药物制剂。在此药物制剂中,含有本发明的一个化合物和可用于药物的载体。此载体可以是固体、半固体、液体稀释剂的形式或胶囊。这些药物制剂也是本发明的另一部分。通常活性化合物的量占制剂重量的0.1~95%之间。胃肠道外给药的制剂是占重量的0.2~20%之间,口服给药的制剂是占重量的1~50%之间。
在以剂量单位形式口服用的,含有本发明化合物的药物制剂的制备过程中,所选的化合物可与固体的、粉末状的载体混合(如乳糖、蔗糖、山梨醇、甘露糖醇、淀粉、支链淀粉、纤维素衍生物、明胶或其他适宜的载体)和润滑剂(如硬脂酸镁、硬脂酸钙、钠stery富马酸盐和聚乙二醇腊等。然后此混合物加工成颗粒或压制成片。含亚砜的颗粒和药片可包上肠溶包衣,此包衣可使剂型在胃内时活性物质不受酸的降解作用。此肠溶包衣选自可用于药物的肠溶包衣材料,如蜂蜡、紫胶、阴离子成膜聚合物如邻苯二甲酸乙酸纤维素、邻苯二甲酸羟丙甲基纤维素、部分甲酯化的甲基丙烯酸聚合物等等,如果再加上适宜的增塑剂就更好。在此包衣中加入不同的染料,以区别含不同活性化合物或活性化合物含量不同的片剂或颗粒。
软明胶胶囊可由含有一个(或多个)本发明的化合物、植物油、脂肪或其适合于软明胶胶囊的赋形剂的混合物的膜片制成。软明胶胶囊也可由上述肠溶材料包衣。硬明胶胶囊可含有活性化合物的颗粒或其肠溶包衣颗粒。硬明胶胶囊颗粒还可以含有与固体粉末状的载体,如乳糖、蔗糖、山梨醇、甘露糖醇、土豆淀粉、支链淀粉、纤维素衍
生物或明胶等混合的活性化合物。此硬明胶胶囊可如上述肠溶包衣。
直肠给药的剂量单位可制成栓剂形式,它是活性物质与中性脂肪基质的混合物;或制成明胶直肠胶囊,它是活性物质与植物油、液体石腊、或其他合适的明胶直肠胶囊赋形剂的混合物;或可制成成药形式的微量灌肠剂的形式,恰在给药前以适宜的溶剂调制。
口服给药的液体制剂可制成糖浆式悬浮剂,如含0.2%到20%(重量)的活性成份的溶液或悬浮剂,其余的部分是糖或糖醇和乙醇、水、甘油、丙二醇和聚乙二醇的混合物。需要时,液体制剂可以含有调色剂、调味剂、糖精和羧甲基纤维素或其他增调剂。液体口服制剂也可制成干粉剂,用前以适宜的溶剂调制。
胃肠道外给药的溶液可制成本发明的化合物溶于可用于药物的溶剂中的溶液形式。最好的浓度是0.1%~10%(重量)。此溶液也可含有稳定剂和/或缓冲剂,制成不同单位剂量的安瓶或管瓶。胃肠道外给药的溶液,也可制成干剂,用前以适宜的溶剂临时调制。
活性物质的典型剂量的变化范围很宽,取决于很多因素,如各病人的个人需要量、给药的途径和疾病。一般来说,口服和胃肠道外给药,在每日5~500毫克活性物质的范围内。
下面举例说明本发明
例2 醋酸〔2-〔〔(3,5-二甲基-4-甲氧基-2-吡啶基)甲基〕亚磺酰〕-1H-苯并咪唑-1-基〕甲酯钠盐的制备
(方法A)
在搅拌下,向溶于水(20毫升)中的氢氧化钠(0.48克,0.012摩尔)中,加入2-〔〔(3,5-二甲基-4-甲氧基-2-吡啶基)甲基〕亚磺酰)-1H-苯并咪唑(1.89克,
0.006摩尔)和硫酸氢四丁铵(2.04克,0.006摩尔)。此混合物在室温下搅拌约5分钟,然后用二氯甲烷(30毫升)提取三次,合并分离出的二氯甲烷相,以硫酸钠干燥,过滤,蒸发除去溶剂,得到油状物。残余的油状物溶解在甲苯(40毫升)中,加热至+60℃。在保护气体和搅拌下,加入溶解在干燥甲苯(10毫升)中的乙酸氯甲基酯(0.72克,0.0066摩尔)。此溶液在+60℃下放置过夜。蒸发除去甲苯,残余的油状物在硅胶柱上作层析,以甲醇∶二氯甲烷(5∶95)作洗脱液,在异丙醚中重结晶产物,得到产物(0.39克,17%)。通过核磁共振分析确认为标题产物。
例1和3-6
在下面例1和3-6所列的化合物可用例2所例举的方法制备。
例7 己二酸〔2-〔〔(3,5-二甲基-4-甲氧基-2-吡啶基)甲基〕亚磺酰〕-1H-苯并咪唑-1-基〕甲基单酯钠盐的制备
己二酸〔2-〔〔3,5-二甲基-4-甲氧基-2-吡啶基)甲基〕亚磺酰〕-1H-苯并咪唑-1-基〕甲基氯甲基酯(0.60克,0.0011摩尔)(按方法A合成)溶解在50%的乙腈水溶液(40毫升)中,在连续搅拌下,缓慢加入三个当量的氢氧化钠水溶液。蒸除乙腈,残余物用二氯甲烷洗涤,蒸除残余的水,得到油状残余物,在硅胶上作层析,以乙酸乙酯-乙醇作洗脱液,得到所要的化合物(0.02克)。产物的鉴定由核磁共振确认。
例8.对苯二甲酸〔2-〔〔(4-甲氧基-3,5-二甲基-2-吡啶基)甲基〕亚磺酰〕-1H-苯并咪唑-1-基〕-甲基单酯钠盐的制备。(方法C)
向对苯二甲酸(166克,0.01摩尔)的四氢呋喃(50毫升)溶液中,加入二异丙基乙基胺(2.6克,0.02摩尔),混合物冷至-10℃。搅拌下滴加溶解在四氢呋喃(20毫升)中的氯甲酸异丁酯(1.36克,0.01摩尔)。加完后,混合物的温度升至+15℃,滴加溶解在四氢呋喃(20毫升)中的〔2-〔〔(4-甲氧基-3,5-二甲基-2-吡啶基)甲基〕亚磺酰〕-1H-苯并咪唑-1-基〕-甲醇,室温下搅拌此混合物2小时。蒸除四氢呋喃,残余物溶解在二氯甲烷中,用水洗涤。蒸发分离后的二氯甲烷相,残余的油状物溶解在乙酸乙酯中,加入水,用氢氧化钠(1M)调pH至2.5。蒸发分离的乙酸乙酯相,残余物溶解在二氯甲烷中,用硫酸钠干燥,过滤,蒸除溶剂,得到所要的化合物(产量0.8克,16%)。得到的标题化合物的鉴定由核磁共振确认。
例9.N,N-二甲基-β-丙氨酸〔2-〔〔(4-甲氧基-3,5-二甲基-2-吡啶基)甲基〕亚磺酰〕-1H-苯并咪唑-1-基〕-甲酯的制备。(方法C)
将N,N-二甲基-β-丙氨酸(0.76克,0.005摩尔)和N-甲基吗啉(0.99克,0.01摩尔)加入到二氯甲烷(15毫升)中。溶液冷至-10℃,在惰性气体下加入溶解在二氯甲烷(15毫升)中的氯甲酸异丁酯(0.68克,0.005摩尔)。在-10℃搅拌此溶液约20分钟。在-10℃下将溶解在二氯甲烷(15毫升)中的〔2-〔〔(4-甲氧基-3,5-二甲基-2-吡啶基)甲基〕-亚磺酰〕-1H-苯并咪唑-1-基〕-甲醇滴加到此混酐中,此溶液在-10℃下搅拌2小时,然后温度升至室温。搅拌下加入氢氧化钠溶液(25毫升,0.24),混合物搅拌约5
分钟。分离后的二氯甲烷相,以硫酸钠干燥,过滤,蒸发溶液,得到所要的化合物(产量0.7克,32%)。标题化合物的鉴定由核磁共振确认。
熔点:>230°。
例10和12
表2中的例10和例12所列的化合物是用方法C制备的。
例11 N,N-二乙基甘氨酸〔2〔〔(4-甲氧基-3,5-二甲基-2-吡啶基)甲基〕亚磺酰〕-1H-苯并咪唑-1-基〕甲酯(方法C)
〔2〔〔(4-甲氧基-3,5-二甲基-2-吡啶基)甲基〕亚磺酰〕-1H-苯并咪唑-1-基〕甲醇(3.5克,0.010摩尔)、N,N-二环己基碳化二亚胺(2.1克,0.010摩尔)、N,N-二乙基甘氨酸氯化氢盐(1.7克。0.010摩尔)和4-二甲基氨基吡啶(1.3克,0.011摩尔)在吡啶(75毫升)中的混合物在室温下搅拌39小时。过滤除去沉淀出来的N,N-二环己基脲。蒸发滤液,残余物溶解在二氯甲烷中。二氯甲烷溶液用溶解在水(25毫升)中的氢氧化钠(0.080克,0.0020摩尔)洗涤,然后用水(25毫升)洗一次。有机相干燥(硫酸钠),过滤,蒸发除去溶剂,得到所要的产物。产物的鉴定由核磁共振确认。
例1~12的化合物的鉴定数据列于下表3
中间体的制备
苯甲酸氯甲酯的制备
在干燥多聚甲醛(7.5克,0.75摩尔)的存在下,将苄基氯(35克,0.25摩尔)和熔融氯化锌(1.0克,0.0073摩尔)
表3 本发明化合物的鉴定数据
核磁共振分析数据δ ppm(500MHz)
例 溶剂
1.15(s,9H),2.3(s,3H),2.35(s,3H),2.4(s,3H),
1. CDCl32.45(s,3H),4.9-5.0(q,2H),6.35-6.40(q,2H),7.3(s,
1H),7.35(s,1H),7.55(s,1H),8.2(s,1H),
2.5(s,3H),2.6(s,3H),2.7(s,3H),4.15(s,3H),
2. CDCl35.35(s,2H),6.85-6.95(q,2H),7.75-7.9(m,2H),
8.5(d,1H),8.25(d,1H),8.55(s,1H)
2.2(s,3H),2.25(s,3H),3.7(s,3H),4.95-5.1(q,2H),
3. CDCl36.7-6.8(q,2H),7.3-7.5(m,4H),7.55(t,1H),7.75
(d,1H),7.85(d,1H),8.05(d,2H),8.15(s,1H)
1.3(t,3H),2.0(d,3H),2.3(s,6H),3.8(s,3H),4.2-
4. CD3OD 4.35(m,4H),5.0(d,1H),5.2(d,1H),7.4-7.6(m,2H),
7.8(d,1H),7.9(d,1H),9.2(s,1H)
1.25(t,3H),2.15(s,3H),2.25(s,3H),3.7(s,3H),
5. CDCl34.05-4.4(q,2H),5.0(s,2H),6.35-6.75(q,2H),7.35-
8.0(m,4H),8.2(s,1H)
6. (90 MHz) 2.15(s,3H),2.20(s,3H),3.55-5.05(m,12H),
CDCl36.55(dd,2H),7.3-7.95(m,4H),8.2(s,1H)
7. (50C MHz) 1.55-1.75(m,4H),2.25(s,3H),2.3(s,3H),2.25(t,3H),
CD3OD 2.45(t,2H),3.8(s,3H),5.05(dd,2H),6.5(dd,2H),
7.45(dd,1H),7.5(dd,1H),7.55-7.65(m,2H),8,10(s,1H)
表3(接上页)
核磁共振分析数据 ppm(500MHz)
例 溶剂
2.1(s,3H),2.15(s,3H),3.65(s,3H),4.8-5.05(q,2H)
8. DMSO 6.7(d,2H),7.35(t,1H),7.45(t,1H),7.75(d,1H),
7.8-8(m,4H),8.05(s,1H)
2.15(s,6H),2.2(s,3H),2.25(s,3H),2.26(t,2H),
9. CDCl33.75(s,3H),4.95(s,2H),6.4-6.55(q,2H),7.25-7.5
(m,2H),7.6(d,1H),7.8(d,1H),8.1(s,1H)
2.25(s,3H),2.4(s,3H),3.8(s,3H),4.85(s,2H),5.4
10. CDCl3(s,2H),6.4(s,2H),7.3(d,1H),7.35-7.5(m,2H),7.65
(d,1H),8.05-8.15(q,4H),8.25(s,1H)
0.85-1.0(t,6H),2.15(s,3H),2.25(s,3H),2.45-2.7
11. (90MHz) (q,4H),3.4(s,2H),3.7(s,3H),5.0(s,2H),6.55
(s,2H),7.3-7.95(m,4H),8.2(s,1H)
0.9(d,6H),1.95(m,1H),2.2(s,3H),2.3(s,3H),3.95
12. CDCl3(d,2H),4.95-5.05(q,2H),6.45-6.65(q,2H),7.4-7.55
(m,2H),7.7(d,1H),7.85(d,1H),8.2(s,1H)
加热2小时,得到一油状物,真空蒸馏得到所要的化合物(175克,41%)。产物的鉴定由核磁共振确认;δ(500MHZ;CDCL3),6.0(S,2H),7.5(dd,2H),7.65(t,1H),8.1(d,2H)。
〔2-〔〔(4-甲氧基-3,5-二甲基-2-吡啶基)甲基〕-亚磺酰〕-1H-苯并咪唑-1-基〕甲醇的制备
将2-〔〔(4-甲氧基-3,5-二甲基-2-吡啶基)-甲基〕亚磺酰〕-1H-苯并咪唑(3.15克,10毫摩尔)和N,N-二甲基氨基吡啶(120毫克,1毫摩尔)溶解在二氯甲烷(50毫升)中,加入甲醛溶液(5M、10毫升,50毫摩尔),激烈搅拌此混合物2分钟。分离各相。二氯甲烷溶液干燥(硫酸钠),过滤,蒸发至干,得到基本纯的微红的残余的油状标题物。
核磁共振:500MHZ,CDCL3,δ:2.15、2.27,3.70、4.89、5.89、7.33、7.63、7.96。
下列处方举例说明了含有本发明化合物作为有效成份的药物制剂:
由下列成分制成含1%(单位体积的重量)活性物质的糖浆:
例7的化合物 1.0克
糖粉 30.0克
糖精 0.6克
甘油 5.0克
调味剂 0.05克
乙醇 96% 5.0克
蒸馏水适量,加至使体积成 100毫升
糖及糖精溶解于60克温水中,冷却后,活性物质加入到糖溶液中,加入甘油及溶解在乙醇中的调味剂溶液。混合物同水稀释成100毫升。
肠溶包衣片
含活性物质20毫克的肠溶包衣片由下述成分制成:
Ⅰ 例5的化合物 200克
乳糖 700克
甲基纤维素 6克
聚乙烯吡咯烷酮(交联的) 50克
硬脂酸镁 15克
碳酸钠 6克
蒸馏水 适量
Ⅱ 乙酸邻苯二甲酸纤维素 200克
十六烷醇 15克
异丙醇 2000克
二氯甲烷 2000克
Ⅰ 例5化合物的粉末与乳糖混合,用甲基纤维素和碳酸钠的水溶液制粒。将湿料压过筛子,在干燥箱内干燥颗粒。颗粒干燥后与聚乙烯吡咯烷酮及硬脂酸镁混合。此干混合物在压片机上,用直径6毫米的冲头压制成片芯(10,000片),每片含20毫克活性物质。
静脉给药的溶液
每毫升含4毫克活性化合物的、静脉用的胃肠道外给药制剂,由下列成分制成:
例8的化合物 4克
聚乙二醇400(注射用) 400克
磷酸氢二钠 适量
无菌水加至最后体积成 1000毫升
活性化合物溶解在聚乙二醇400中,加入550毫升水,加入磷酸氢二钠水溶液使溶液pH成7.4,加水使最后体积成1000毫升。溶液通过0.22微米过滤器过滤,并立即分装入10毫升无菌安瓶中,封闭安瓶。
生物试验
在有知觉的狗的体内胃酸分泌的抑制作用
试验方法
使用慢性胃瘘管狗,这些狗曾做外科手术在胃内装上胃插管和十二指肠瘘管,后者用于在十二指肠直接给以试验化合物。
手术后恢复四周以后,每只狗每周做一次试验。每次试验前18小时不给食物和水。
悬浮在0.5%Methocel
(90HG 15000,Dow Chem Corp)中的试验化合物或者用胃管口服,或者通过十二指肠瘘的插管十二指肠内给药。在连续灌注组氨(各剂量为400~600微摩尔/千克,小时)诱导分泌胃酸1小时后,造成大致90%的最大胃酸分泌。在两小时内,收集从胃插管自流的胃液样品,每次收集连续30分钟。样品用自动放射滴定仪,以0.1摩尔/升浓度的氢氧化
钠滴定至pH7.0,计算出酸量。相对于对照试验中只给赋形剂的狗,由每只狗的出酸量,计算出胃分泌的抑制百分数,测定出每个化合物的抑制作用的峰值。
在下表4中给出试验结果:
表4.狗中的胃酸抑制作用
试验化合物 实验化合物的给药量(口服给 胃酸分泌的
药、微摩尔/公斤) 抑制作用
例2 8 75%
例3 2 95%
Claims (15)
1、一种制备式Ⅰ化合物及其生理上可接受的盐的方法,式Ⅰ为:
其中:
X是-SO-;
R1、R2、R3和R4,相同或不相同,代表:
(a)H;
(b)含1-6个碳原子的烷基;
R5代表:
(a)含1-6个碳原子的烷基;
(b)含1-6个碳原子的单或二羟基取代的烷基;
(c)被氨基,单烷基氨基,其中烷基部分含1-3个碳原子,和二烷基氨基,其中各烷基部分含1-3个碳原子,取代的含1-6个碳原子的烷基;
(d)羧基取代的1-7全碳原子的烷基,其中羧基可选作钠、钾盐形式;
(f)含1-6个碳原子的烷氧基;
(g)单或二羟基取代的含1-6个碳原子的烷氧基;
(n)被羧基取代的苯基,其中羧基可选自钠、钾盐形式;R6和R8是相同的或不相同的,选自:
(a)H;
(b)含1-6个碳原子的烷基;
R7是(a)H;
(b)含1-7个碳原子的烷基;
(c)含1-7个碳原子的烷氧基;
R9是(a)H;
(b)含1-4个碳原子的烷基;
但须:
当下列条件(a1)-(a3)同时满足时,R7是氢、烷基;
(a1)R1和R4都是氢;
(a2)R2和R3选自氢、烷基、和
(a3)R5是烷基、以酸形式的羧基取代的烷基、氨基取代的烷基,或R5是被羧基取代的苯基;
该方法包括:
A.式Ⅱ化合物与式Ⅲ化合物的反应,
其中R1、R2、R3、R4、R6、R7、R8和X的定义同上,M是选自Na+、K+和Li的金属阳离子,或是四级铵盐离子,
其中R5和R9的定义同上,Y是卤素,或作用相当的离去基团;
C.式Ⅳ化合物与式Ⅴ化合物或其活性衍生物反应,制备R9是氢的式Ⅰ化合物
其中R1、R2、R3、R4、R6、R7、R8和X的定义同上,
其中R5的定义同上;以上各反应生成的式Ⅰ化合物若为游离碱可加有机或无机酸使之成盐。
2、按照权利要求1的方法,其中起始原料化合物中的R5是甲基。
3、按照权利要求1的方法,其中起始原料化合物中的R5是羧基取代的苯基,该羧基在苯环的4-位上。
4、按照权利要求1的方法,其中起始原料化合物中的R5是以盐的形式存在的含烷基1-3个碳原子的二烷基-氨基取代的1-6个碳原子的烷基。
5、按照权利要求1的方法,其中起始原料化合物中的R5是以盐的形式存在的含1-3个碳原子的二烷基-氨基取代的含1-6个碳原子的烷氧基。
6、按照权利要求1的方法,其中起始原料化合物中的苯并咪唑核1-位上的取代基是:
-CH(CH3)OCOOC2H5
-CH2OCOOC2H5
-CH2OCOOCH2CH(CH3)3
-CH2OCOOCH2CH(OH)CH2OH
-CH2OCOCH2CH2CH2CH2COO-Na+
-CH2OCOCH2N(CH3)2
-CH2OCOCH2N(C2H5)2
-CH2OCOCH2CH2N(CH3)2
-CH2OCOCH2CH2N(C2H5)2
-CH2OCOCH2CH2CH2N(CH3)2
-CH2OCOOCH2CH2N(CH3)2
-CH2OCOOCH2N(CH3)2
-CH2OCONHCH2COOH或
其中含氨基基团可任选作盐的形式,羧基可任选作盐的形式或酯的形式。
7、按照权利要求1的方法,其中起始原料化合物中的R1、R2、R3和R4都是H。
8、按照权利要求1的方法,其中起始原料化合物中的R2和R3是氢,R1和R4是含1-6个碳原子的烷基。
9、按照权利要求1的方法,其中起始原料化合物中的R7是含1-6个碳原子的烷基或含1-6个碳原子的烷氧基。
10、按照权利要求1的方法,其中起始原料化合物中的R9是氢或甲基。
11、按照权利要求10的方法,其中起始原料化合物中的R9是氢。
14、按照权利要求1的方法,其中起始原料化合物中的X、R1、R2、R3和R4的定义与其在权利要求1中的定义相同;R5的定义与其在权利要求3中的定义相同;R6、R7和R8的定义与其在权利要求9、12或13的定义相同。
15、按照权利要求1的方法,其中起始原料的结构式基团与式Ⅰ基团相适应,制得的化合物是式Ⅰ化合物中的一种化合物,该化合物中的基团为:
X R1R2R3R4R5R6R7R8R9
SO H CH3CH3H C(CH3)3CH3H CH3H
SO H H H H -OC2H5CH3OCH3CH3CH3
SO H H H H -OC2H5CH3OCH3CH3H
SO H H H H OCH2CHOHCH2OH CH3OCH3CH3H
SO H H H H (CH2)4COO-Na+CH3OCH3CH3H
SO H H H H -(CH2)2-N(CH3)2CH3OCH3CH3H
SO H H H H -CH2-N(C2H5)2CH3OCH3CH3H
SO H H H H OCH2CH(CH3)2CH3OCH3CH3H
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8505112-6 | 1985-10-29 | ||
SE8505112A SE8505112D0 (sv) | 1985-10-29 | 1985-10-29 | Novel pharmacological compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
CN86107595A CN86107595A (zh) | 1987-07-08 |
CN1022487C true CN1022487C (zh) | 1993-10-20 |
Family
ID=20361960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN86107595A Expired - Lifetime CN1022487C (zh) | 1985-10-29 | 1986-10-29 | 制备新的药物化合物 |
Country Status (31)
Country | Link |
---|---|
US (1) | US5021433A (zh) |
EP (2) | EP0233284B1 (zh) |
JP (2) | JPH0780874B2 (zh) |
KR (1) | KR950009858B1 (zh) |
CN (1) | CN1022487C (zh) |
AT (1) | ATE79619T1 (zh) |
AU (1) | AU598491B2 (zh) |
CS (1) | CS272767B2 (zh) |
DD (1) | DD252375A5 (zh) |
DE (1) | DE3686483T2 (zh) |
DK (1) | DK320587A (zh) |
EG (1) | EG17753A (zh) |
ES (1) | ES2051696T3 (zh) |
FI (1) | FI91151C (zh) |
GR (1) | GR3006177T3 (zh) |
HU (1) | HU198474B (zh) |
IE (1) | IE59167B1 (zh) |
IL (1) | IL80437A0 (zh) |
IS (1) | IS1564B (zh) |
JO (1) | JO1502B1 (zh) |
LT (1) | LTIP1681A (zh) |
LV (1) | LV10270B (zh) |
MY (1) | MY101791A (zh) |
NO (1) | NO171365C (zh) |
NZ (1) | NZ218028A (zh) |
PH (1) | PH25319A (zh) |
PL (1) | PL150240B1 (zh) |
PT (1) | PT83647B (zh) |
SE (1) | SE8505112D0 (zh) |
WO (1) | WO1987002668A1 (zh) |
ZA (1) | ZA867716B (zh) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ222495A (en) * | 1986-11-21 | 1991-04-26 | Haessle Ab | Benzimidazole derivatives and pharmaceutical compositions |
WO1990003373A1 (en) * | 1988-09-20 | 1990-04-05 | Hisamitsu Pharmaceutical Co., Inc. | NOVEL DIBENZ[b,e]OXEPIN DERIVATIVES |
IE64199B1 (en) * | 1988-12-22 | 1995-07-12 | Haessle Ab | Compound with gastric acid inhibitory effect and process for its preparation |
SE8804629D0 (sv) * | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
US5049674A (en) * | 1989-12-20 | 1991-09-17 | Aktiebolaget Hassle | Therapeutically active fluoro substituted benzimidazoles |
US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
US5274099A (en) * | 1989-12-20 | 1993-12-28 | Aktiebolaget Hassle | Therapeutically active fluoro substituted benzimidazoles |
SE9002206D0 (sv) * | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
PL166209B1 (pl) * | 1990-06-20 | 1995-04-28 | Astra Ab | Sposób wytwarzania nowych pochodnych benzimidazolu PL |
ES2048109B1 (es) * | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
WO1995032957A1 (en) * | 1994-05-27 | 1995-12-07 | Astra Aktiebolag | Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles |
BR9912937A (pt) | 1998-08-10 | 2001-05-08 | Partnership Of Michael E Garst | Pró-drogas de inibidores de bomba de prótons |
US6093734A (en) * | 1998-08-10 | 2000-07-25 | Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin | Prodrugs of proton pump inhibitors |
US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
US6369087B1 (en) * | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
EP1334971A4 (en) * | 2000-10-12 | 2004-05-12 | Takeda Chemical Industries Ltd | BENZIMIDAZOLE COMPOUNDS, METHOD FOR THE PRODUCTION AND USE THEREOF |
EP1437352A4 (en) * | 2001-09-25 | 2004-12-08 | Takeda Chemical Industries Ltd | BENZYMIDAZOLE COMPOUND, PROCESS FOR PRODUCING AND USING THE SAME |
ATE437642T1 (de) * | 2002-06-14 | 2009-08-15 | Takeda Pharmaceutical | Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren |
RU2292342C2 (ru) * | 2002-07-19 | 2007-01-27 | Уинстон Фармасьютикалс ЛЛС. | Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса |
CA2493618A1 (en) | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
US8802139B2 (en) * | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
WO2005039640A1 (en) * | 2003-10-03 | 2005-05-06 | Allergan Inc. | Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs |
US20050075371A1 (en) * | 2003-10-03 | 2005-04-07 | Allergan, Inc. | Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
US20070161679A1 (en) * | 2004-02-18 | 2007-07-12 | Allergan, Inc. | Method and compositions for the intravenous administration of compounds related to proton pump inhibitors |
JP2007523163A (ja) * | 2004-02-18 | 2007-08-16 | アラーガン、インコーポレイテッド | プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物 |
CA2561700A1 (en) * | 2004-04-16 | 2005-12-15 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
EP1740571B1 (en) | 2004-04-28 | 2009-07-29 | Hetero Drugs Limited | A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers |
PT1748998E (pt) | 2004-05-28 | 2010-03-24 | Hetero Drugs Ltd | Novo processo de síntese estereoselectiva de sulfóxidos de benzimidazol |
US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
CN101453993A (zh) * | 2006-04-03 | 2009-06-10 | 伊萨·奥迪迪 | 含有机溶胶涂层的受控释放递送物件 |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
WO2008036201A1 (en) * | 2006-09-19 | 2008-03-27 | Alevium Pharmaceuticals, Inc. | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety |
EP2086543A2 (en) | 2006-10-27 | 2009-08-12 | The Curators of the University of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
CA2716367C (en) | 2008-02-20 | 2015-05-26 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
US9107911B2 (en) | 2010-01-07 | 2015-08-18 | Alkermes Pharma Ireland Limited | Prodrugs of heteraromatic compounds |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR320097A (fr) * | 1902-04-01 | 1902-12-01 | Betts | Perfectionnements dans et relatifs au raffinage électrolytique du plomb et des alliages de plomb |
FR1474663A (fr) * | 1966-04-06 | 1967-03-24 | Electrolyt Zinc Australasia | Procédé d'extraction de métaux |
US4026776A (en) * | 1970-12-02 | 1977-05-31 | Mitsui Mining & Smelting Co., Ltd. | Method for producing high purity lead |
SE418966B (sv) * | 1974-02-18 | 1981-07-06 | Haessle Ab | Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan |
US4045564A (en) * | 1974-02-18 | 1977-08-30 | Ab Hassle | Benzimidazole derivatives useful as gastric acid secretion inhibitors |
US3960681A (en) * | 1974-02-21 | 1976-06-01 | Mitsui Mining & Smelting Co., Ltd. | Method for producing electrolytic high purity lead using large-sized electrodes |
SE416649B (sv) * | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
NZ181123A (en) * | 1975-06-30 | 1979-12-11 | Univ Melbourne | Treatment of mineralcontaining materials with an acid in the presence of fluoride ion |
US3972790A (en) * | 1975-09-26 | 1976-08-03 | Uop Inc. | Production of metallic lead |
IN148930B (zh) * | 1977-09-19 | 1981-07-25 | Hoffmann La Roche | |
US4189461A (en) * | 1977-11-30 | 1980-02-19 | Kennecott Copper Corporation | Metal leaching from concentrates using nitrogen dioxide in acids |
SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
FR2446863A1 (fr) * | 1979-01-22 | 1980-08-14 | Uop Inc | Procede perfectionne de recuperation de plomb |
FR2453906A1 (fr) * | 1979-04-12 | 1980-11-07 | Uop Inc | Procede de preparation hydrometallurgique de plomb a l'aide d'une extraction par voie electrochimique |
US4229271A (en) * | 1979-05-24 | 1980-10-21 | Rsr Corporation | Method of recovering lead values from battery sludge |
US4359465A (en) * | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
CH644116A5 (de) * | 1980-08-21 | 1984-07-13 | Hoffmann La Roche | Imidazolderivate. |
FR2505876A1 (en) * | 1981-05-12 | 1982-11-19 | Noual Patrick | Selective winning of lead from sulphide ores - by leaching with hot aq. hydro:fluorosilicic acid soln. contg. hydrogen peroxide and air so only lead is dissolved |
SE8300736D0 (sv) * | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
US4500398A (en) * | 1984-06-20 | 1985-02-19 | The United States Of America As Represented By The Secretary Of The Interior | Production of lead from sulfides |
AU568441B2 (en) * | 1984-09-24 | 1987-12-24 | Upjohn Company, The | 2-(pyridylalkenesulfinyl) benzimidazole derivatives |
ZA856671B (en) * | 1984-09-24 | 1986-04-30 | Upjohn Co | N-substituted derivatives of 2-(pyridylaklenesulfinyl)benzimidazoles as gastric antisecretory agents |
-
1985
- 1985-10-29 SE SE8505112A patent/SE8505112D0/xx unknown
-
1986
- 1986-10-09 ZA ZA867716A patent/ZA867716B/xx unknown
- 1986-10-22 EG EG661/86A patent/EG17753A/xx active
- 1986-10-22 NZ NZ218028A patent/NZ218028A/xx unknown
- 1986-10-23 IE IE280586A patent/IE59167B1/en not_active IP Right Cessation
- 1986-10-24 PH PH34408A patent/PH25319A/en unknown
- 1986-10-27 DD DD86295633A patent/DD252375A5/de not_active IP Right Cessation
- 1986-10-27 JO JO19861502A patent/JO1502B1/en active
- 1986-10-27 MY MYPI86000038A patent/MY101791A/en unknown
- 1986-10-28 EP EP86906498A patent/EP0233284B1/en not_active Expired - Lifetime
- 1986-10-28 IL IL80437A patent/IL80437A0/xx not_active IP Right Cessation
- 1986-10-28 DE DE8686906498T patent/DE3686483T2/de not_active Expired - Fee Related
- 1986-10-28 EP EP86850378A patent/EP0221041A3/en active Pending
- 1986-10-28 HU HU865443A patent/HU198474B/hu not_active IP Right Cessation
- 1986-10-28 KR KR1019870700555A patent/KR950009858B1/ko active IP Right Grant
- 1986-10-28 ES ES86906498T patent/ES2051696T3/es not_active Expired - Lifetime
- 1986-10-28 AT AT86906498T patent/ATE79619T1/de not_active IP Right Cessation
- 1986-10-28 WO PCT/SE1986/000493 patent/WO1987002668A1/en active IP Right Grant
- 1986-10-28 IS IS3156A patent/IS1564B/is unknown
- 1986-10-28 AU AU65429/86A patent/AU598491B2/en not_active Ceased
- 1986-10-28 JP JP61505700A patent/JPH0780874B2/ja not_active Expired - Lifetime
- 1986-10-29 CS CS782686A patent/CS272767B2/cs unknown
- 1986-10-29 CN CN86107595A patent/CN1022487C/zh not_active Expired - Lifetime
- 1986-10-29 PL PL1986262105A patent/PL150240B1/pl unknown
- 1986-10-29 PT PT83647A patent/PT83647B/pt not_active IP Right Cessation
-
1987
- 1987-06-24 DK DK320587A patent/DK320587A/da not_active Application Discontinuation
- 1987-06-26 NO NO872686A patent/NO171365C/no unknown
- 1987-06-29 FI FI872864A patent/FI91151C/sv not_active IP Right Cessation
-
1988
- 1988-05-12 US US07/195,343 patent/US5021433A/en not_active Expired - Fee Related
-
1992
- 1992-11-05 GR GR920402498T patent/GR3006177T3/el unknown
-
1993
- 1993-06-30 LV LVP-93-856A patent/LV10270B/xx unknown
- 1993-12-28 LT LTIP1681A patent/LTIP1681A/xx not_active Application Discontinuation
-
1994
- 1994-12-21 JP JP6318132A patent/JPH0826014B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1022487C (zh) | 制备新的药物化合物 | |
CN1050605C (zh) | 环烷并吲哚和环烷并氮杂吲哚衍生物,其制备方法和含有它们的药物组合物 | |
CN1052227C (zh) | 作为粘结受体拮抗剂的噁唑烷酮,其制备方法和含它们的药物组合物 | |
CN1028992C (zh) | 1,4,-苯并硫杂吖庚因衍生物的制备方法 | |
CN1058212A (zh) | 取代的莱并咪唑、其制备方法和其在药物上的用途 | |
CN1020098C (zh) | 硫代内酰胺-n-乙酸衍生物的生产 | |
CN1013274B (zh) | 头孢菌素衍生物的制备方法 | |
CN1021226C (zh) | 头孢菌素衍生物的制备方法 | |
CN1008738B (zh) | 头孢菌素衍生物的制备方法 | |
CN1036713C (zh) | 碳代青霉烯衍生物、其中间体、制备方法和含它的药物组合物 | |
CN1074904A (zh) | 苯并呋喃基-和噻吩基甲硫基-链烷羧酸衍生物 | |
CN1216547A (zh) | 质子泵抑制剂 | |
CN1208333C (zh) | 主要用于治疗骨质疏松的吲哚衍生物 | |
CN1133844A (zh) | 氧杂-或硫杂脂族桥连喹喔啉-2,3-二酮 | |
CN1021967C (zh) | 新的喹啉衍生物的制备方法 | |
CN1021735C (zh) | 新型青霉烯化合物的制备方法 | |
CN1031533A (zh) | 稳定的1-氧青霉烯-3-羧酸 | |
CN1049156A (zh) | 茚并吲哚化合物 | |
CN1073446A (zh) | 取代的苯并咪唑及其制备工艺和用途 | |
CN1041596A (zh) | 稳定的氧青霉烯-3-羟酸的制备及其作为β-内酰胺酶抑制剂的应用 | |
CN1045955C (zh) | 喹啉衍生物及其制法和用途以及含该衍生物的药物组合物 | |
CN1184221C (zh) | 有7-(7-氨甲基-5-氮杂螺[2,4]庚烷)取代基的新喹啉羧酸衍生物及其制备方法 | |
CN1285593C (zh) | 吡咯并哒嗪衍生物 | |
CN1096298A (zh) | 七位上含有取代的氧亚氨基的新型头孢菌素、它们的制备方法和中间体及作为药物的用途 | |
CN1102645A (zh) | 杂环取代的苯基乙酸的苯基甘氨酰胺类衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |